Sarna G, Mitsuyasu R, Figlin R, Ambersley J, Groopman J
Cancer Chemother Pharmacol. 1985;14(1):12-4. doi: 10.1007/BF00552717.
Vinzolidine, a semisynthetic vinca alkaloid, was studied as oral therapy in 30 patients with Kaposi's sarcoma, non-small cell lung cancer, colorectal cancer, and breast cancer. Substantial variations in morbidity were observed among the patients, some patients receiving doses up to 45 mg/m2 without toxicity while others had severe hematologic toxicity at doses as low as 25 mg/m2. Nausea/vomiting and diarrhea also occurred. Responses were seen in two of 11 patients with Kaposi's sarcoma but not in other patients. Unpredictable severe hematologic toxicity led to early closure of this study. The heterogeneity of patient tolerance may relate to variable oral drug bioavailability, and it is conceivable that vinzolidine could be administered more safely by the IV route.
长春利定，一种半合成的长春花生物碱，在30例患有卡波西肉瘤、非小细胞肺癌、结直肠癌和乳腺癌的患者中作为口服疗法进行了研究。在患者中观察到发病率有很大差异，一些患者接受高达45mg/m²的剂量却没有毒性，而另一些患者在低至25mg/m²的剂量时就出现了严重的血液学毒性。恶心/呕吐和腹泻也有发生。11例卡波西肉瘤患者中有2例出现反应，但其他患者未出现反应。不可预测的严重血液学毒性导致该研究提前终止。患者耐受性的异质性可能与口服药物生物利用度的差异有关，可以想象长春利定通过静脉途径给药可能更安全。
